Improving medication management for patients with multiple long-term conditions
Co-design of a Seamless Person-centered Intervention to Optimize Medication Use Across Healthcare Levels
This study is trying to improve how medications are managed for people with multiple health conditions when they leave the hospital, by working with patients, their families, and healthcare workers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oslo University College Academic / other |
| Locations | 1 site (Oslo) |
| Trial ID | NCT05421143 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on optimizing medication use for patients with multimorbidity by co-designing a person-centered intervention. It addresses the challenges of medication interactions and communication gaps during transitions of care, particularly at hospital discharge. The study builds on previous research that highlighted the need for better medication communication and patient empowerment. By involving healthcare personnel and next of kin, the study aims to enhance the overall medication management process for patients transitioning from hospital to home or nursing care.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older, living in Oslo, who manage their medications independently and are scheduled for hospital discharge while using at least four regular medications.
Not a fit: Patients who are terminally ill, isolated due to infections, or have previously participated in the study may not benefit from this intervention.
Why it matters
Potential benefit: If successful, this intervention could significantly improve medication management and quality of life for patients with multiple long-term conditions.
How similar studies have performed: Previous studies have shown some success in improving medication management through pharmacist interventions, but this specific approach is novel in its focus on co-design and person-centered care.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients: * Adult ≥ 18 years * Gives written, informed consent to participate in the study. If the patient is not competent to consent, consent can be obtained from the patient's next of kin. * Residential address in Oslo * Lives at home and normally manage their medications themselves (might have help from home-care nurses or next of kin) * Scheduled to be discharged from the wards to their home or to short-term stay in nursing homes * Uses at least four regular medications from at least two therapy classes (Anatomical Therapeutic Chemical (ATC) at first level Health care personnel (HCP) and next of kin: * Expected to be involved in the included patient's medication regime or management after hospital discharge * Able and willing to give written, informed consent to participate in the study * HCP should be general practitioners (GPs) or home-care nurses. Exclusion Criteria: Patients: * Terminal and/or isolated due to infections * Has previously been included in the study * Has advanced cognitive failure, in accordance with assessment from treating physician * Will not be discharged from the included wards to their homes (for example planned transfer to another ward or long-term stay at nursing home) * Unable to communicate in Norwegian or English HCP and next of kin: * Unable to communicate in Norwegian or English * HCP or next of kin that has previously been included in the study
Where this trial is running
Oslo
- Oslo University Hospital — Oslo, Norway (Recruiting)
Study contacts
- Principal investigator: Malin O Syversen, Msc — University of Oslo
- Study coordinator: Malin O Syversen, Msc
- Email: m.o.syversen@farmasi.uio.no
- Phone: +4748126091
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.